Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Cogent Biosciences Inc COGT

Healthcare Biotechnology
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other... see more

Recent & Breaking News (NDAQ:COGT)

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire 12 days ago

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) 

GlobeNewswire January 20, 2026

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

GlobeNewswire January 12, 2026

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2026

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis

GlobeNewswire December 30, 2025

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

GlobeNewswire December 8, 2025

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)

GlobeNewswire December 6, 2025

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

GlobeNewswire November 14, 2025

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031

GlobeNewswire November 11, 2025

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock

GlobeNewswire November 10, 2025

Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)

GlobeNewswire November 10, 2025

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results 

GlobeNewswire November 3, 2025

Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

GlobeNewswire November 3, 2025

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 24, 2025

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib

GlobeNewswire October 20, 2025

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 29, 2025

Cogent Biosciences Announces Participation in the Citi Biopharma Conference

GlobeNewswire August 26, 2025

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results

GlobeNewswire August 5, 2025

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 10, 2025

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

GlobeNewswire July 8, 2025

Podcasts